FUNDAMENTALS · Fundamentals · TW Healthcare

TaiMed Biologics (4147) Fundamentals 2026 — Revenue Analysis | SniperIQ

TaiMed Biologics (4147) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT

5.8B, trading at NT$58.40 on the TWO. This SniperIQ fundamentals page covers TaiMed Biologics's valuation, profitability (net margin -20.9%), revenue (NT$611M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
5.8B
Net Margin-20.9%
Revenue (FY25)NT$611M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is TaiMed Biologics's market cap?

TaiMed Biologics (4147) has a market capitalization of approximately NT

5.8B, trading at NT$58.40 on the TWO. Market cap moves with the live share price.

What is TaiMed Biologics's P/E ratio?

TaiMed Biologics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is TaiMed Biologics?

TaiMed Biologics runs a net profit margin of -20.9%, a gross margin of 45.2%, and an operating margin of -26.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does TaiMed Biologics generate?

TaiMed Biologics reported revenue of NT$611M for fiscal year 2025, with net income of -NT

68M and earnings per share (EPS) of -0.61. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does TaiMed Biologics pay a dividend?

TaiMed Biologics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is TaiMed Biologics financially healthy?

TaiMed Biologics carries a debt-to-equity ratio of 0.13x and a current ratio of 16.83x, with a market beta of -0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is TaiMed Biologics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TaiMed Biologics (4147) the key facts are: market cap NT

5.8B, revenue NT$611M, 52-week range 47-85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track TaiMed Biologics's full fundamentals live

Get TaiMed Biologics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Jazz Pharmaceuticals (JAZZ) fundamentals · ACRO Biomedical (6748) fundamentals · Caliway Biopharmaceuticals (6919) fundamentals · BGI Genomics (300676) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons